{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/contraception-ius-iud/background-information/types/","result":{"pageContext":{"chapter":{"id":"9dbc8287-ded7-50ad-a43e-d87edeebb462","slug":"types","fullItemName":"Types","depth":2,"htmlHeader":"<!-- begin field e879d7e5-de13-4f96-ab2d-acce01211966 --><h2>What types of intrauterine contraception are available in the UK?</h2><!-- end field e879d7e5-de13-4f96-ab2d-acce01211966 -->","summary":"","htmlStringContent":"<!-- begin item 61fa5dfc-edfb-4ac2-8fe5-87400d6721a6 --><!-- begin field fac02968-7b35-4913-a785-acce01211966 --><ul><li><strong>Two types of intrauterine contraception (IUC) are available in the UK:</strong><ul><li>The levonorgestrel intrauterine system (LNG-IUS) — a polyethylene T-shaped intrauterine device with a levonorgestrel reservoir around the vertical stem.</li><li>The copper intrauterine device (Cu-IUD) — a non-hormonal intrauterine device that comes in various shapes and sizes. Most Cu-IUDs are composed of plastic with copper wire or fitted with copper bands, while some also have a central core of silver to prevent copper fragmentation.</li></ul></li><li><strong>Four types of LNG-IUS are currently available:</strong><br><ul><li>Mirena® 20 micrograms/24 hours intrauterine delivery system (contains 52 mg of levonorgestrel) — licensed duration of use: up to 5 years for contraception and idiopathic menorrhagia, and 4 years for protection from endometrial hyperplasia during oestrogen replacement therapy.</li><li>Levosert® 20 microgram/24 hours intrauterine delivery system (contains 52 mg of levonorgestrel) — licensed duration of use: up to 5 years for contraception and heavy menstrual bleeding.</li><li>Kyleena® 19.5 mg intrauterine delivery system (contains 19.5 mg of levonorgestrel) — licensed duration of use: up to 5 years for contraception.</li><li>Jaydess® 13.5 mg intrauterine delivery system (contains 13.5 mg of levonorgestrel — licensed duration of use: up to 3 years for contraception.</li></ul></li><li><strong>Several types of Cu-IUDs are available, and the most effective ones contain at least 380 mm<sup>2</sup> of copper and have copper bands on the transverse arms (banded devices). </strong>Available types include: <ul><li>Framed IUDs with 380 mm<sup>2</sup> (copper in stem and arms), for example:<ul><li>TCu380A QuickLoad® — duration of use: 10 years.</li><li>TT380® Slimline — duration of use: 10 years.</li><li>Copper T380A — duration of use: 10 years.</li><li>Mini TT380® Slimline — duration of use: 5 years.</li><li>T–Safe® 380A QL — duration of use: 10 years.</li><li>Flexi-T® 380 — duration of use: 5 years.</li></ul></li><li>Framed IUDs with 380 mm<sup>2</sup> (copper in stem only), for example:<ul><li>UT 380 Short® — duration of use: 10 years.</li><li>UT 380 Standard® — duration of use: 10 years.</li><li>Neo-Safe® T380 — duration of use: 5 years.</li><li>Nova-T® 380 — duration of use: 5 years.</li><li>Novaplus T 380® Ag (mini and normal version) — duration of use: 5 years.</li><li>Novaplus T 380® Cu (mini and normal) — duration of use: 5 years.</li></ul></li><li>Framed IUDs with less than 380 mm<sup>2</sup> copper, for example:<ul><li>Flexi-T® 300.</li><li>Load® 375.</li><li>Multiload® Cu 375.</li><li>Multi–Safe® 375.</li><li>Ancora® 375Cu.</li></ul></li><li>Frameless IUDs, for example:<ul><li>GyneFix® (contains 300 mm<sup>2</sup> copper).</li></ul></li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/contraception-ius-iud/references/\">FSRH, 2019a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/contraception-ius-iud/references/\">Joint Formulary Committee, 2020</a>]</p><!-- end field fac02968-7b35-4913-a785-acce01211966 --><!-- end item 61fa5dfc-edfb-4ac2-8fe5-87400d6721a6 -->","topic":{"id":"5fd4f695-2824-524f-97fd-1ffbc1ed1ad6","topicId":"14c8f64d-295a-4e1a-92b1-5280c3cce30f","topicName":"Contraception - IUS/IUD","slug":"contraception-ius-iud","lastRevised":"Last revised in February 2021","chapters":[{"id":"fa63ff86-38d1-5d04-b121-e6ba3a5b60d3","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"a6a86d04-8f24-5c92-b340-fe91a3323c4f","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"841f70dc-d28e-5fb0-a68a-d6dac27e0ffb","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"5c7dee41-86ab-5d74-b647-984a7323f97c","slug":"changes","fullItemName":"Changes"},{"id":"24837e86-76a3-581e-ae6a-b827bf3bd948","slug":"update","fullItemName":"Update"}]},{"id":"abaf741b-ff01-59e1-8db9-510b749e87b7","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"b6f49269-86ef-5810-8059-10d065f377f0","slug":"goals","fullItemName":"Goals"},{"id":"a95a933e-1a31-5be4-9009-21b8a79da2ae","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"defba0ce-4495-5c71-8bfb-d04ee36d79e9","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"f24f3c36-9720-5dd2-a7c5-8552fd694e1c","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"ff8474b0-1358-5b27-8928-58d81c1aeb7a","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - options for local implementation"},{"id":"f10c46df-f19e-51c2-bd07-c680f266f212","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"7a441ab2-b820-5821-8c27-5a2e71c741aa","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"c7698130-9973-5145-aa0e-981a48972d36","slug":"definition","fullItemName":"Definition"},{"id":"9dbc8287-ded7-50ad-a43e-d87edeebb462","slug":"types","fullItemName":"Types"},{"id":"35c8bc48-3518-55a7-ae5a-a86db3ff3a56","slug":"mode-of-action","fullItemName":"Mode of action"},{"id":"aab10d36-adb8-52f6-895c-f7ce73e2ef4c","slug":"efficacy","fullItemName":"Efficacy"},{"id":"91843ac0-bc35-5798-b0e9-da4d52b30a69","slug":"advantages-disadvantages","fullItemName":"Advantages and disadvantages"},{"id":"6058a967-a6d7-52cd-9cf5-d2d480ec4d7d","slug":"where-to-obtain","fullItemName":"Where to obtain"}]},{"id":"98bf4d7c-c4c4-5c19-9821-a8c43bb9b0fe","fullItemName":"Management","slug":"management","subChapters":[{"id":"3aef47bd-6fd3-5fc1-a254-61098a484a64","slug":"levonorgestrel-intrauterine-system","fullItemName":"Scenario: Levonorgestrel intrauterine system"},{"id":"52ed621a-9a40-532d-ac51-ba401911db84","slug":"copper-intrauterine-device","fullItemName":"Scenario: Copper intrauterine device"}]},{"id":"08730ed3-ce27-5f45-b6fa-9747b4d35a64","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"cfebd8c6-03b3-541a-8425-4f73a4eafe81","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"23a8e2fd-3eac-5088-919c-f81757e13399","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"0f38e730-f213-59fe-afba-bf3f2f2b92e1","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"64158eb2-3052-5f75-872c-1f839e443457","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"a8fc3514-5b7d-55bb-a8d1-c58fb846dde6","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"71aff73b-554d-5df3-b36c-cc7490291d7f","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"fb77b532-9628-57cb-a96d-9533a61e730c","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"7a441ab2-b820-5821-8c27-5a2e71c741aa","slug":"background-information","fullItemName":"Background information"},"subChapters":[]}}},"staticQueryHashes":["3666801979"]}